Subjects

Abstract

TISSUE factor, a member of the cytokine-receptor superfamily and high-affinity receptor and cofactor for plasma factor Vll/VIIa (ref. 1), is the primary cellular initiator of blood coagulation. It is involved in thrombosis and inflammation associated with sepsis, atherosclerosis and cancer2, and can participate in other cellular processes including intracellular signalling3, metastasis4, tumour-associated angiogenesis5, and embryogenesis6. Here we report that inactivation of the tissue factor gene (TF) results in abnormal circulation from yolk sac to embryo beyond embryonic day 8.5, leading to embryo wasting and death. Vitelline vessels from null mice were deficient in smooth-muscle α-actin-expres-sing mesenchymal cells, which participate in organization of the vessel wall. This implies that tissue factor has a role in bloodvessel development.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , & Thromb. Haemost 66, 67–79 (1991).

  2. 2.

    , & Cancer Metast. Rev. 11, 237–248 (1992).

  3. 3.

    , , , & J. Biol. Chem. 270, 4650–4660 (1995).

  4. 4.

    , , & Proc. Natl Acad. Sci. USA 89, 11832–11836 (1992).

  5. 5.

    et al. J. Clin. Invest. 94, 1320–1327 (1994).

  6. 6.

    et al. Am. J. Pathol. 149, 101–113 (1996).

  7. 7.

    et al. Development 121, 1845–1854 (1995).

  8. 8.

    & Trends Genet. 11, 359–366 (1995).

  9. 9.

    , & Teratology 44, 581–590 (1991).

  10. 10.

    et al. Proc. Natl Acad. Sci. USA 91, 7598–7602 (1994).

  11. 11.

    , & Dev. Dyn. 204, 228–239 (1995).

  12. 12.

    , & FASEB J. 9, 910–918 (1995).

  13. 13.

    et al. Nature Genet. 11, 155–163 (1995).

  14. 14.

    & Histochemistry 99, 1–12 (1993).

  15. 15.

    FASEB J. 9, 860–865 (1995).

  16. 16.

    , , , & Nature 381, 516–519 (1996).

  17. 17.

    , , , & Thromb. Haemost. 75, 389–392 (1996).

  18. 18.

    et al. Genes Dev. 9, 2020–2033 (1995).

  19. 19.

    et al. J. Clin. Invest. 92, 2746–2755 (1993).

  20. 20.

    et al. Nature 380, 435–439 (1996).

  21. 21.

    et al. J. Neuropathol. Exp. Neurol. 51, 206–219 (1992).

  22. 22.

    et al. Histochem. Cell. Biol. 104, 397–405 (1995).

  23. 23.

    , & Br. J. Haematol. 90, 939–405 (1995).

Download references

Author information

Affiliations

  1. Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, B-3000 Leuven, Belgium

    • Peter Carmeliet
    • , Lieve Moons
    • , Lise Van Vlaenderen
    •  & Désiré Collen
  2. Departments of Immunology and Vascular Biology, The Scripps Research Institute, La Jolla, California, CA 92037, USA

    • Nigel Mackman
    •  & Thomas Edgington
  3. Institute of Pathology, Technical University of Dresden, Dresden 01307, Germany

    • Thomas Luther
    • , Michael Kasper
    •  & Martin Müller
  4. Laboratoire de Neurologie du Developpement, Höpital Robert Debré, Paris 75019, France

    • Pierre Gressens
    •  & Philippe Evrard
  5. Laboratory of Experimental Hematology, University Hospital Leuven, Leuven B-3000, Belgium

    • Hilde Demunck
  6. Max Planck Institut für Physiologische und Klinische Forschung, W.G. Kerckhoff-lnstitut, Abteilung Molekulare Zellbiologie, Bad Nauheim, Germany

    • Georg Breier
    •  & Werner Risau

Authors

  1. Search for Peter Carmeliet in:

  2. Search for Nigel Mackman in:

  3. Search for Lieve Moons in:

  4. Search for Thomas Luther in:

  5. Search for Pierre Gressens in:

  6. Search for Lise Van Vlaenderen in:

  7. Search for Hilde Demunck in:

  8. Search for Michael Kasper in:

  9. Search for Georg Breier in:

  10. Search for Philippe Evrard in:

  11. Search for Martin Müller in:

  12. Search for Werner Risau in:

  13. Search for Thomas Edgington in:

  14. Search for Désiré Collen in:

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/383073a0

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.